MohammadSadeghi Ashkan, Farjadian Fatemeh, Alipour Shohreh
Department of Quality Control, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.
Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Iran J Basic Med Sci. 2021 Mar;24(3):331-340. doi: 10.22038/ijbms.2021.49866.11385.
Ocular inserts are usually polymeric thin films with increased ocular residence time and sustained drug release capacity. Sodium alginate is a biocompatible and biodegradable carrier; however, initial burst release of encapsulated drug within it, is recognized as a challenge. Grafting -addition of functional moieties to a polymer- is a technique to modify polymers' physicochemical properties, including higher ability to control drug release. Linezolid (LNZ) solution is used in consecutive doses in treatment of antibiotic-resistant Gram-positive bacterial infections especially induced by methicillin resistant (MRSA).
Grafted alginate copolymers were synthesized using butyl methacrylate (BMC) and lauryl methacrylate (LMC) at two different reaction times (12 hr and 24 hr). Copolymerization was evaluated by H-NMR, Ft-IR, and TGA. Copolymer safety was examined by cytotoxicity test against HEK-293 cell. Linezolid inserts were prepared using optimized copolymers and characterized.
H-NMR, Ft-IR, and TGA confirmed the successful grafting of alginate copolymers. ALG-B24 and ALG-L12 showed the highest safety against HEK-293 cell line comparing with intact alginate. Linezolid insert characterization results indicated a slower linezolid release profile related to creation of a lipophilic structure. A better strength property for linezolid loaded ALG-B24 and ALG-L12 inserts was obtained while ALG-L12 showed a stronger adhesive force compared with intact alginate. Antibacterial efficacy on clinical isolated MRSA after 24 hr was similar to linezolid solution.
Lipophilic alginate copolymer (ALG-L12) showed a sustained release capability while retaining its main feature in strong film forming ability so it seems to be a promising safe carrier.
眼用插入剂通常是具有延长眼内滞留时间和持续释药能力的聚合物薄膜。海藻酸钠是一种生物相容性和可生物降解的载体;然而,其中包封药物的初始突释被认为是一个挑战。接枝——向聚合物中添加功能基团——是一种改变聚合物物理化学性质的技术,包括更高的控释能力。利奈唑胺(LNZ)溶液连续给药用于治疗耐抗生素革兰氏阳性菌感染,尤其是耐甲氧西林(MRSA)引起的感染。
使用甲基丙烯酸丁酯(BMC)和甲基丙烯酸月桂酯(LMC)在两个不同反应时间(12小时和24小时)合成接枝海藻酸共聚物。通过1H-NMR、傅里叶变换红外光谱(Ft-IR)和热重分析(TGA)评估共聚反应。通过对HEK-29细胞的细胞毒性试验检测共聚物安全性。使用优化后的共聚物制备利奈唑胺插入剂并进行表征。
1H-NMR、Ft-IR和TGA证实了海藻酸共聚物接枝成功。与完整海藻酸钠相比,ALG-B24和ALG-L12对HEK-29细胞系显示出最高安全性。利奈唑胺插入剂表征结果表明,由于形成了亲脂性结构,利奈唑胺释放曲线较慢。负载利奈唑胺的ALG-B24和ALG-L12插入剂具有更好的强度性能,而ALG-L12与完整海藻酸钠相比显示出更强的粘附力。24小时后对临床分离的MRSA的抗菌效果与利奈唑胺溶液相似。
亲脂性海藻酸共聚物(ALG-L12)显示出持续释放能力,同时保留了其强成膜能力的主要特性,因此似乎是一种有前景的安全载体。